Cell Tissue Technology Sdn Bhd (CTT) is a Malaysian-based company established as a spin-off from the National University of Malaysia or UKM. One of the early ideas behind the formation is to manufacture and commercialize MyDerm™ - an autologous tissue engineered medical product researched and developed by the Tissue Engineering Centre of UKM.
Currently there are less than 10 companies in the country adopting advanced medical technology as their core business activities. Many are still wedged at the pre-commercialization stage and none has boasts any success story in the market. CTT aims to be at the forefront of Malaysia's advanced medical industry in areas of tissue engineering and regenerative medicine. Our first step towards this direction is our introduction of MyDerm™, the first tissue engineered human skin in Malaysia.
ABOUT MyDERM™ - THE JOURNEY
MyDerm™ is an advanced 3D autologous skin substitute meant for the repair of full thickness skin loss. This skin substitute is permanent, able to replace the traditional skin and have proven to enhance wound healing.
MyDerm™ is used mainly to replace skin loss due to burns, injuries, diseases and infections.
MyDerm™'s contribution to the medical scene is enormous and significant, more so for diabetic patients who generally suffer from poor wound healing. The prevention of infections to open wounds will reduce greatly the dreaded solution of amputation.
As such, CTT is confident that the introduction of MyDerm™ will revolutionize the local medical industry, bringing hope and solutions to people who need it – doctors, patients, surgeons, consultants, etc.
To ensure its effectiveness and safety, MyDerm™ will be extensively used clinically on patients. The research and development for this product was completed in big animal study and Limited Clinical Application in June 2008. The prototype also underwent several tests such as "Toxicology for Safety”, "Rejection on Implantation” and "Flowcytometry Cell Cycle Analysis”. There were no incidents of infections, graft losses, excessive bleeding or hematoma. Patients reported less pain, less scaring and discoloration after treatment.
CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm